$APVO
Aptevo Therapeutics Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021043955 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $3.110M $473.0K
YoY Change 557.51% -93.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.110M $2.840M
YoY Change 44.72% -56.56%
% of Gross Profit
Research & Development $4.722M $4.440M
YoY Change 6.35% -42.58%
% of Gross Profit
Depreciation & Amortization $298.0K $300.0K
YoY Change -0.67% -48.28%
% of Gross Profit
Operating Expenses $4.722M $7.280M
YoY Change -35.14% -30.03%
Operating Profit -$5.722M -$6.807M
YoY Change -15.94% -47.22%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$2.342M $4.000K
YoY Change -58650.0% -100.92%
Pretax Income -$8.064M -$6.800M
YoY Change 18.59% -37.27%
Income Tax
% Of Pretax Income
Net Earnings -$7.932M -$6.803M
YoY Change 16.6% -48.96%
Net Earnings / Revenue -255.05% -1438.27%
Basic Earnings Per Share -$1.75
Diluted Earnings Per Share -$1.75 -$2.105M
COMMON SHARES
Basic Shares Outstanding 4.537M
Diluted Shares Outstanding 4.537M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.39M $7.600M
YoY Change 694.66% -63.81%
Cash & Equivalents $61.65M $10.15M
Short-Term Investments
Other Short-Term Assets $2.261M $2.600M
YoY Change -13.04% -17.98%
Inventory
Prepaid Expenses
Receivables $3.110M $300.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $65.77M $10.50M
YoY Change 526.33% -75.96%
LONG-TERM ASSETS
Property, Plant & Equipment $4.963M $6.600M
YoY Change -24.8% 43.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $746.0K $757.0K
YoY Change -1.45% -39.34%
Total Long-Term Assets $5.709M $8.009M
YoY Change -28.72% -64.29%
TOTAL ASSETS
Total Short-Term Assets $65.77M $10.50M
Total Long-Term Assets $5.709M $8.009M
Total Assets $71.47M $18.51M
YoY Change 286.16% -72.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.196M $4.662M
YoY Change 11.45% -60.84%
Accrued Expenses $1.493M $2.000M
YoY Change -25.35% -44.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $10.67M $0.00
YoY Change
Total Short-Term Liabilities $30.86M $7.000M
YoY Change 340.91% -57.83%
LONG-TERM LIABILITIES
Long-Term Debt $4.323M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $22.41M $2.900M
YoY Change 672.62% 22207.69%
Total Long-Term Liabilities $26.73M $2.900M
YoY Change 821.69% -85.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.86M $7.000M
Total Long-Term Liabilities $26.73M $2.900M
Total Liabilities $57.59M $9.900M
YoY Change 481.75% -75.21%
SHAREHOLDERS EQUITY
Retained Earnings -$200.8M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.88M $8.650M
YoY Change
Total Liabilities & Shareholders Equity $71.47M $18.50M
YoY Change 286.35% -72.02%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$7.932M -$6.803M
YoY Change 16.6% -48.96%
Depreciation, Depletion And Amortization $298.0K $300.0K
YoY Change -0.67% -48.28%
Cash From Operating Activities -$5.057M -$4.630M
YoY Change 9.22% -70.88%
INVESTING ACTIVITIES
Capital Expenditures -$392.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$392.0K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.20K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.318M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.057M -4.630M
Cash From Investing Activities -392.0K 0.000
Cash From Financing Activities 8.318M 0.000
Net Change In Cash 2.869M -4.630M
YoY Change -161.97% -71.08%
FREE CASH FLOW
Cash From Operating Activities -$5.057M -$4.630M
Capital Expenditures -$392.0K
Free Cash Flow -$4.665M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2152000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3239000
apvo Increase Decrease In Assets And Liabilities Held For Sale
IncreaseDecreaseInAssetsAndLiabilitiesHeldForSale
-1719000
CY2020Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
we effected a 1-for-14 reverse stock split (the “Reverse Split”) of our common stock pursuant to which every 14 shares of our common stock issued and outstanding as of March 26, 2020 were automatically combined into one issued and outstanding share of common stock. No fractional shares were issued as a result of the reverse stock split.
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.071
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.071
CY2019Q1 apvo Pre Funded Warrants And Rights Outstanding Term
PreFundedWarrantsAndRightsOutstandingTerm
P10Y
apvo Increase Decrease In Long Term Operating Lease Liability
IncreaseDecreaseInLongTermOperatingLeaseLiability
491000
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.78
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.03
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.10
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3232811
us-gaap Profit Loss
ProfitLoss
-15188000
us-gaap Profit Loss
ProfitLoss
-3906000
us-gaap Share Based Compensation
ShareBasedCompensation
1146000
us-gaap Share Based Compensation
ShareBasedCompensation
714000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
588000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
764000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-5000
apvo Increase Decrease In Long Term Operating Lease Liability
IncreaseDecreaseInLongTermOperatingLeaseLiability
470000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
14338000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2104000
apvo Non Cash Interest Expense And Other
NonCashInterestExpenseAndOther
2354000
apvo Non Cash Interest Expense And Other
NonCashInterestExpenseAndOther
137000
apvo Increase Decrease In Royalties Receivable
IncreaseDecreaseInRoyaltiesReceivable
741000
apvo Increase Decrease In Royalties Receivable
IncreaseDecreaseInRoyaltiesReceivable
288000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1359000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-499000
apvo Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
563000
apvo Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
496000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12557000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15808000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
28120000
CY2021Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:RoyaltyMember
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
473000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8446000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4110000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2840000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10084000
CY2021Q1 apvo Payment Of Royalty Purchase Agreement Percentage
PaymentOfRoyaltyPurchaseAgreementPercentage
1.90
CY2021Q1 apvo Payment Of Royalty Interest Percentage
PaymentOfRoyaltyInterestPercentage
0.50
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4440000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12610000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14429000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8057000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6456000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5722000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6807000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2342000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3124000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-271000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2104000
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
132000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
546000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
12898000
us-gaap Net Income Loss
NetIncomeLoss
-15188000
us-gaap Net Income Loss
NetIncomeLoss
-3906000
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-2.10
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-3.51
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-5.14
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.12
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
3.95
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.39
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.19
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4477821
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3269410
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
582000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
574000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7256000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
10504000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-582000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28120000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10550000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
22104000
apvo Repayments Under Liability Related To Sale Of Future Royalties
RepaymentsUnderLiabilityRelatedToSaleOfFutureRoyalties
2421000
apvo Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
35000000
apvo Transaction Costs From Sale Of Future Royalties
TransactionCostsFromSaleOfFutureRoyalties
1100000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
111000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
985000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
86000
CY2021Q1 apvo Issuance Of Common Stock From Exercise Of Warrants
IssuanceOfCommonStockFromExerciseOfWarrants
506000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2021Q2 apvo Issuance Of Common Stock From Exercise Of Warrants
IssuanceOfCommonStockFromExerciseOfWarrants
478000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10234000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
572000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7932000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
13881000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11842000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
301000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6803000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
8650000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7900000
us-gaap Net Income Loss
NetIncomeLoss
-15200000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-200800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12600000
CY2020Q1 apvo Fractional Shares Reverse Stock Split
FractionalSharesReverseStockSplit
0
apvo Milestone Payment
MilestonePayment
227000
CY2021Q2 apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
132000
apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
319000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
413000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
2897000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
15152000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
0
CY2021Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, forecasted royalties, effective interest rates, clinical accruals, useful lives of equipment, commitments and contingencies, and stock-based compensation forfeiture rates. Given the global economic climate and additional or unforeseen effects from the COVID-19 pandemic, these estimates are becoming more challenging, and actual results could differ materially from those estimates.</p>
CY2021Q1 apvo Proceeds From Sale Of Investments
ProceedsFromSaleOfInvestments
35000000
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
-1580000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
14338000
apvo Depreciation Or Capital Expenditures
DepreciationOrCapitalExpenditures
0
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
132000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
546000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
12898000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
14300000
apvo Investing Non Cash Items
InvestingNonCashItems
0
apvo Investing Non Cash Items
InvestingNonCashItems
0
CY2020Q2 apvo Depreciation Or Capital Expenditures
DepreciationOrCapitalExpenditures
0
CY2021Q2 us-gaap Cash
Cash
4498000
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
55896000
CY2021Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
1259000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
2555000
CY2020Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
25000000.0
CY2020Q4 us-gaap Business Acquisition Description Of Acquired Entity
BusinessAcquisitionDescriptionOfAcquiredEntity
This acquisition of voting stock triggered a change in control, resulting in an Event of Default under Section 10.1(a)(ii) of the Credit Agreement. On November 10, 2020, the Company obtained a waiver from MidCap Financial pursuant to which, among other things, MidCap Financial waived such Event of Default and MidCap Financial and the Company agreed that an immediate event of default under the Credit Agreement will be deemed to have occurred in the event that (a) a majority of the seats on the Company’s board of directors are occupied by persons who were neither (i) nominated by the Company’s board of directors nor (ii) appointed by the directors so nominated, and (b) Tang has appointed the majority of the Company’s board of directors. No other events of default have occurred with respect to the Credit Agreement.
CY2021Q1 apvo Payment Of Amount Outstanding
PaymentOfAmountOutstanding
10000000.0
CY2021Q1 apvo Proceeds From Sale Of Investments
ProceedsFromSaleOfInvestments
35000000.0
CY2021Q1 apvo Payment Of Royalty Interest Percentage
PaymentOfRoyaltyInterestPercentage
0.50
CY2021Q1 apvo Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
33920000
CY2021Q2 apvo Non Cash Interest Expense
NonCashInterestExpense
1848000
CY2021Q2 us-gaap Payments For Royalties
PaymentsForRoyalties
2421000
CY2021Q2 apvo Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
33347000
CY2021Q2 apvo Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
-12810000
CY2021Q2 apvo Liability Related To Sale Of Future Royalties Non Current
LiabilityRelatedToSaleOfFutureRoyaltiesNonCurrent
20537000
apvo Operating Lease Property Number Of Lab Equipment
OperatingLeasePropertyNumberOfLabEquipment
1
apvo Operating Lease Property Number Of Copiers
OperatingLeasePropertyNumberOfCopiers
4
apvo Finance Lease Number Of Equipment
FinanceLeaseNumberOfEquipment
1
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2021Q2 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
395000
CY2021Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1000
CY2021Q2 us-gaap Lease Cost
LeaseCost
396000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2159000
us-gaap Operating Lease Payments
OperatingLeasePayments
698000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1900000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1449
CY2021Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-8064000
CY2021Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
132000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7932000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6803000
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.78
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-2.10
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-3.51
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-5.14
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.03
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.12
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
3.95
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.75
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.39
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.19
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4536517
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3232811
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4477821
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3269410
CY2021Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10200
CY2021Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
24.8
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
301000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1146000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
714000
CY2019Q1 apvo Prefunded Warrant Expiration Date
PrefundedWarrantExpirationDate
2029-03-11

Files In Submission

Name View Source Status
0001564590-21-043955-index-headers.html Edgar Link pending
0001564590-21-043955-index.html Edgar Link pending
0001564590-21-043955.txt Edgar Link pending
0001564590-21-043955-xbrl.zip Edgar Link pending
apvo-10q_20210630.htm Edgar Link pending
apvo-10q_20210630_htm.xml Edgar Link completed
apvo-20210630.xsd Edgar Link pending
apvo-20210630_cal.xml Edgar Link unprocessable
apvo-20210630_def.xml Edgar Link unprocessable
apvo-20210630_lab.xml Edgar Link unprocessable
apvo-20210630_pre.xml Edgar Link unprocessable
apvo-ex311_8.htm Edgar Link pending
apvo-ex312_6.htm Edgar Link pending
apvo-ex321_11.htm Edgar Link pending
apvo-ex322_10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending